Lentiviral Vectors: From Wild-Type Viruses to Efficient Multi-Functional Delivery Vectors.
Level 5 - mechanism / opinion, no new human data
Narrative review of vector biology and manufacturing strategies without primary human data.
PubMed 40943418 · doi:10.3390/ijms26178497
What was done
This narrative review summarizes molecular optimization strategies for lentiviral vector manufacturing, focusing on modifications to plasmids and producer cell lines to improve vector safety, integrity, potency, and yield. It also surveys engineered vector modalities expanding applications beyond traditional ex vivo DNA transfer to include RNA and protein delivery, in vivo targeting, vaccinology, and gene editing.
What was found
The abstract reports no quantitative data or effect sizes. It describes qualitative observations that vector manufacturing is stochastic and that small modifications to production components can substantially affect final yield depending on specific genetic payloads and envelope proteins.
Why it matters
It outlines how technical refinements in vector manufacturing and cargo packaging extend lentiviral applications from standard gene addition to diverse delivery platforms such as in vivo therapeutics and gene editing.
Limits
The abstract contains no primary experimental data, quantitative comparisons, or systematic review methodology. Practical feasibility and yields remain highly variable and payload-dependent.
Cited by
- supports Lentiviral vectors used to deliver genetic material in CAR-T cell therapies are engineered from modified human immunodeficiency virus (HIV).